Review



fak inhibitor pf 562271  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress fak inhibitor pf 562271
    Fak Inhibitor Pf 562271, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf 562271/product/MedChemExpress
    Average 94 stars, based on 30 article reviews
    fak inhibitor pf 562271 - by Bioz Stars, 2026-02
    94/100 stars

    Images



    Similar Products

    fak inhibitor pf 562271  (MedChemExpress)
    94
    MedChemExpress fak inhibitor pf 562271
    Fak Inhibitor Pf 562271, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf 562271/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    fak inhibitor pf 562271 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    fak inhibitor faki  (MedChemExpress)
    94
    MedChemExpress fak inhibitor faki
    Fak Inhibitor Faki, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor faki/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    fak inhibitor faki - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    fak inhibitor pf562271  (MedChemExpress)
    94
    MedChemExpress fak inhibitor pf562271
    Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and <t>PF562271</t> (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.
    Fak Inhibitor Pf562271, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf562271/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    fak inhibitor pf562271 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    fak inhibitor  (Selleck Chemicals)
    94
    Selleck Chemicals fak inhibitor
    Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and <t>PF562271</t> (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.
    Fak Inhibitor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor/product/Selleck Chemicals
    Average 94 stars, based on 1 article reviews
    fak inhibitor - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    fak inhibitor pf–562271  (Selleck Chemicals)
    90
    Selleck Chemicals fak inhibitor pf–562271
    Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and <t>PF562271</t> (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.
    Fak Inhibitor Pf–562271, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak inhibitor pf–562271/product/Selleck Chemicals
    Average 90 stars, based on 1 article reviews
    fak inhibitor pf–562271 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    fak signaling inhibitor  (MedChemExpress)
    94
    MedChemExpress fak signaling inhibitor
    Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and <t>PF562271</t> (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.
    Fak Signaling Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak signaling inhibitor/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    fak signaling inhibitor - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    fak selective inhibitor pf 562271  (MedChemExpress)
    94
    MedChemExpress fak selective inhibitor pf 562271
    Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and <t>PF562271</t> (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.
    Fak Selective Inhibitor Pf 562271, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fak selective inhibitor pf 562271/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    fak selective inhibitor pf 562271 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and PF562271 (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.

    Journal: World Journal of Gastroenterology

    Article Title: FBP1 as a key regulator of focal adhesion kinase-mediated hepatic stellate cell activation: Multi-omics and experimental validation

    doi: 10.3748/wjg.v31.i28.107361

    Figure Lengend Snippet: Transcriptomics analysis of differential gene expression. A: Principal component analysis (PCA) of normalized counts PCA showing gene expression variance among normal, carbon tetrachloride (CCl 4 ), and PF562271 (PF) conditions. The first principal component (PC1) explains 59% of the variance, and PC2 explains 8%; B: Volcano plot showing differentially expressed genes (DEGs) between the normal and CCl 4 groups. Significant genes (log2 fold change > 1 or < -1, P < 0.05) are highlighted; C: Volcano plot comparing gene expression between the CCl 4 and PF groups. Significant genes are marked similarly; D: Mfuzz clustering of gene expression. Six gene clusters showing expression changes across the normal, CCl 4 , and PF groups, highlighting condition-specific gene regulation; E: UpSet plot showing the overlap of DEGs between comparisons; F: Venn diagram showing unique and shared DEGs between the normal vs CCl 4 and CCl 4 vs PF groups.

    Article Snippet: LX-2 cells, an activated human HSCs line[ ], were treated with varying concentrations of the FAK inhibitor PF562271 (2.5 μM, 5 μM, 10 μM) based on the IC 50 provided by MCE (MedChem Express).

    Techniques: Gene Expression, Expressing

    Proteomics analysis of differential protein expression. A: Principal component analysis (PCA) of normalized protein counts PCA of protein expression across normal, carbon tetrachloride (CCl₄) and PF562271 (PF) conditions. The first principal component (PC1) explains 39.3% of variance, while PC2 explains 9.5%. The three conditions show clear separation; B: Volcano plot showing differentially expressed proteins between the normal and CCl₄ groups. Significant proteins ( P < 0.05, log2 fold change > 1 or < -1) are highlighted; C: Volcano plot comparing the CCl₄ and PF groups. Significant proteins are marked, indicating differential expression between these two conditions ( P < 0.05); D: Mfuzz clustering of protein expression profiles. Clusters 1, 3, and 4 are shown, highlighting distinct expression trends in normal, CCl₄, and PF conditions; E: UpSet plot showing overlaps of differentially expressed proteins between comparisons (normal vs CCl₄, CCl₄ vs PF) and clusters from Mfuzz analysis; F: Venn diagram showing overlap of differentially expressed proteins between the normal vs CCl₄ and CCl₄ vs PF groups. The diagram indicates unique and shared proteins across the conditions.

    Journal: World Journal of Gastroenterology

    Article Title: FBP1 as a key regulator of focal adhesion kinase-mediated hepatic stellate cell activation: Multi-omics and experimental validation

    doi: 10.3748/wjg.v31.i28.107361

    Figure Lengend Snippet: Proteomics analysis of differential protein expression. A: Principal component analysis (PCA) of normalized protein counts PCA of protein expression across normal, carbon tetrachloride (CCl₄) and PF562271 (PF) conditions. The first principal component (PC1) explains 39.3% of variance, while PC2 explains 9.5%. The three conditions show clear separation; B: Volcano plot showing differentially expressed proteins between the normal and CCl₄ groups. Significant proteins ( P < 0.05, log2 fold change > 1 or < -1) are highlighted; C: Volcano plot comparing the CCl₄ and PF groups. Significant proteins are marked, indicating differential expression between these two conditions ( P < 0.05); D: Mfuzz clustering of protein expression profiles. Clusters 1, 3, and 4 are shown, highlighting distinct expression trends in normal, CCl₄, and PF conditions; E: UpSet plot showing overlaps of differentially expressed proteins between comparisons (normal vs CCl₄, CCl₄ vs PF) and clusters from Mfuzz analysis; F: Venn diagram showing overlap of differentially expressed proteins between the normal vs CCl₄ and CCl₄ vs PF groups. The diagram indicates unique and shared proteins across the conditions.

    Article Snippet: LX-2 cells, an activated human HSCs line[ ], were treated with varying concentrations of the FAK inhibitor PF562271 (2.5 μM, 5 μM, 10 μM) based on the IC 50 provided by MCE (MedChem Express).

    Techniques: Expressing, Quantitative Proteomics